IGF1R-IRS1/2 pharmacological inhibitors act by distinct cellular and molecular mechanisms and reveals vulnerabilities for treatment of acute myeloid leukemia (2021)
- Authors:
- USP affiliated authors: MACHADO NETO, JOÃO AGOSTINHO - ICB ; REGO, EDUARDO MAGALHÃES - FM ; FAÇA, VITOR MARCEL - FMRP ; TRAINA, FABÍOLA - FMRP ; SILVA, JUAN LUIZ COELHO DA - FMRP ; MARTINS, DIEGO ANTONIO PEREIRA - FMRP ; SILVESTRINI, VIRGÍNIA CAMPOS - FMRP
- Unidades: ICB; FM; FMRP
- DOI: 10.1182/blood-2021-153105
- Subjects: LEUCEMIA MIELOIDE AGUDA; LINHAGEM CELULAR; INIBIDORES DE ENZIMAS; RECEPTORES DE INSULINA
- Language: Inglês
- Imprenta:
- Publisher place: Washington
- Date published: 2021
- Source:
- Conference titles: Annual Meeting Abstracts - ASH
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SILVA, Juan Luiz Coelho da et al. IGF1R-IRS1/2 pharmacological inhibitors act by distinct cellular and molecular mechanisms and reveals vulnerabilities for treatment of acute myeloid leukemia. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2021-153105. Acesso em: 11 fev. 2026. , 2021 -
APA
Silva, J. L. C. da, Martins, D. A. P., Silvestrini, V. C., Machado Neto, J. A., Rego, E. M., Smolka, M., et al. (2021). IGF1R-IRS1/2 pharmacological inhibitors act by distinct cellular and molecular mechanisms and reveals vulnerabilities for treatment of acute myeloid leukemia. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1182/blood-2021-153105 -
NLM
Silva JLC da, Martins DAP, Silvestrini VC, Machado Neto JA, Rego EM, Smolka M, Faça VM, Traina F. IGF1R-IRS1/2 pharmacological inhibitors act by distinct cellular and molecular mechanisms and reveals vulnerabilities for treatment of acute myeloid leukemia [Internet]. Blood. 2021 ; 138 1869.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1182/blood-2021-153105 -
Vancouver
Silva JLC da, Martins DAP, Silvestrini VC, Machado Neto JA, Rego EM, Smolka M, Faça VM, Traina F. IGF1R-IRS1/2 pharmacological inhibitors act by distinct cellular and molecular mechanisms and reveals vulnerabilities for treatment of acute myeloid leukemia [Internet]. Blood. 2021 ; 138 1869.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1182/blood-2021-153105 - Inibidores farmacológicos de IGF1R-IRS1/2 atuam por mecanismos distintos e revelam vulnerabilidades para o tratamento da LMA
- MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model
- Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome
- Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells
- The expression of NTAL and its protein interactors is associated with clinical outcomes in acute myeloid leukemia
- Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models
- Stathmin 1 is highly expressed in acute promyelocytic leukemia and microtubule dynamics is a potential target for ATRA-resistant APL cells
- Padronização de modelo xenográfico sistêmico de leucemia linfoide aguda
- The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms
- Stathmin 1 is highly expressed and is inhibited by paclitaxel in acute lymphoblastic leukemia cells
Informações sobre o DOI: 10.1182/blood-2021-153105 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003241008.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
